Apogee Therapeutics, Inc.
APGENasdaqHealthcare · Biological Products, (No Diagnostic Substances) · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | −$285.6M | −$216.9M | −$93.0M | −$30.7M |
| Net income | −$255.8M | −$182.1M | −$84.0M | −$39.8M |
| Total assets | $937.1M | $754.0M | $401.4M | $152.1M |
| Total liabilities | $33.3M | $37.2M | $21.5M | $10.0M |
| Equity | — | — | — | — |
| EPS (diluted) | $-4.22 | $-3.30 | $-3.36 | $-16.16 |
| Shares out. | 68.4M | 58.1M | 48.3M | 0 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −27.3%
- Return on capital (ROCE)
- −31.4%
- Liabilities / assets
- 3.5%
- Debt / equity
- —
- Book value / share
- —
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −3.0%clean
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 2 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Active Not Recruitingreadout ~2026-09A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
- Phase 2Active Not Recruitingreadout ~2026-11A Study Evaluating APG777 in Atopic Dermatitis
- Phase 1Active Not Recruitingreadout ~2026-12An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis
- Phase 2Recruitingreadout ~2029-12A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- T. Rowe Price Investment Management, Inc.Passive (13G)Apr 8, 2026
- Fairmount Funds Management LlcActivist (13D)Mar 27, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- Rtw Investments, LpPassive (13G)Feb 17, 2026
- Wellington Management Group LlpPassive (13G)Feb 10, 2026
- Driehaus Capital Management LlcPassive (13G)Nov 14, 2025
- Fmr LlcPassive (13G)Aug 6, 2025
- Blackrock, Inc.Passive (13G)Jul 16, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Henderson Michael ThomasOfficer — Chief Executive Officer | May 13, 2026 | Sell | 18,659 | $82.05 |
| Dambkowski CarlOfficer — Chief Medical Officer | May 6, 2026 | Option exercise | 4,125 | $22.86 |
| Henderson JaneOfficer — Chief Financial Officer | May 1, 2026 | Sell | 811 | $81.02 |
| Henderson Michael ThomasOfficer — Chief Executive Officer | Apr 16, 2026 | Option exercise | 3,000 | $22.86 |
| Henderson JaneOfficer — Chief Financial Officer | Apr 16, 2026 | Sell | 2,000 | $90.00 |
| Henderson Michael ThomasOfficer — Chief Executive Officer | Apr 8, 2026 | Sell | 17,800 | $82.48 |
| Dambkowski CarlOfficer — Chief Medical Officer | Apr 1, 2026 | Option exercise | 4,125 | $22.86 |
| Henderson JaneOfficer — Chief Financial Officer | Apr 1, 2026 | Sell | 900 | $84.46 |
| Henderson JaneOfficer — Chief Financial Officer | Mar 25, 2026 | Sell | 2,000 | $85.00 |
| Henderson Michael ThomasOfficer — Chief Executive Officer | Mar 11, 2026 | Sell | 8,363 | $74.29 |
| Dambkowski CarlOfficer — Chief Medical Officer | Mar 4, 2026 | Option exercise | 4,125 | $22.86 |
| Henderson JaneOfficer — Chief Financial Officer | Mar 2, 2026 | Sell | 300 | $68.27 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 9.4M | 15.8 | -1.3% |
| Apr 30, 2026 | 9.5M | 14.3 | -0.8% |
| Apr 15, 2026 | 9.6M | 15.5 | -1.7% |
| Mar 31, 2026 | 9.7M | 6.1 | +10.6% |
| Mar 13, 2026 | 8.8M | 10.0 | +2.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Regulation FD disclosureMay 27, 2026
- Regulation FD disclosure · Other material eventMay 27, 2026
- Results of operationsMay 11, 2026
- Director / officer changeApr 24, 2026
- Entered a material agreementMar 25, 2026
- Regulation FD disclosure · Other material eventMar 23, 2026
- Regulation FD disclosure · Other material eventJan 6, 2026
- Results of operations · Regulation FD disclosureNov 10, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KFORM 8-KMay 27, 2026
- 8-KFORM 8-KMay 27, 2026
- 4OWNERSHIP DOCUMENTMay 15, 2026
- 144May 13, 2026
- 10-QMay 11, 2026
- 8-KMay 11, 2026
- 4OWNERSHIP DOCUMENTMay 8, 2026
- 144May 6, 2026
- 4OWNERSHIP DOCUMENTMay 4, 2026
- 144May 1, 2026
- DEFA14AApr 24, 2026
- ARSApr 24, 2026
- DEF 14AApr 24, 2026
- 8-KApr 24, 2026
- 4OWNERSHIP DOCUMENTApr 20, 2026